Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non-muscle-invasive Bladder Cancer

Overview

Journal Eur Urol Open Sci

Date 2022 Mar 4

PMID 35243387

Authors

Anouk E Hentschel

Christian J Blankvoort

Judith Bosschieter

Andre N Vis

R Jeroen A van Moorselaar

Judith E Bosmans

Jakko A Nieuwenhuijzen

Affiliations

Soon will be listed here.

Abstract

Background: Bladder cancer imposes a significant public health burden on the European Union. There is a need for cost-effective treatment and follow-up regimens.

Objective: To assess the cost-effectiveness of immediate mitomycin C (MMC) instillation within 1 d after surgery compared to delayed MMC instillation within 2 wk after surgery with further adjuvant treatment, depending on the patient's risk group.

Design Setting And Participants: This economic evaluation was based on a randomized controlled trial among 2243 Dutch patients with non-muscle-invasive bladder cancer (NMIBC) patients from a health care perspective over a 3-yr time period.

Outcome Measurements And Statistical Analysis: The treatment effect was measured as time to recurrence and recurrence-free survival. Missing effect data were imputed with multiple imputation. Health care utilization and related costs were estimated on the basis of treatment protocols for NMIBC patients in the Netherlands. Statistical uncertainty was estimated using bootstrapping and is graphically presented using cost-effectiveness planes and cost-effectiveness acceptability curves.

Results And Limitations: Time to recurrence was significantly longer for immediate MMC instillation (27.31 mo) than for delayed MMC instillation (24.97 mo), with an adjusted mean difference of 2.21 mo (95% confidence interval [CI] 1.58-2.84). The proportion of patients with recurrence-free survival was significantly higher after immediate MMC instillation (0.65) than after delayed MMC instillation (0.56), with an adjusted mean difference of 0.08 (95% CI 0.06-0.11). Total mean health care costs per patient were significantly lower for immediate MMC instillation (€22 959) than for delayed MMC instillation (€24 624), with an adjusted mean difference of -€1350 (95% CI -€1799 to -€900). The study is limited by the retrospective estimation of costs.

Conclusions: This trial-based cost-effectiveness analysis shows that from a health care perspective, immediate MMC instillation is more effective and less expensive compared to delayed MMC instillation.

Patient Summary: We assessed the cost-effectiveness of immediate bladder instillation of mitomycin C after surgery to reduce the risk of recurrence after removal of the bladder tumor as compared to delayed instillation in a large Dutch population of patients with non-muscle-invasive bladder cancer. We found that immediate instillation was more effective and less expensive than delayed instillation. We conclude that immediate mitomycin C instillation is a cost-effective treatment for non-muscle-invasive bladder cancer.

Citing Articles

Should continuous bladder irrigation be recommended when single instillation of intravesical chemotherapy cannot be used after transurethral resection in low-risk non-muscle invasive bladder cancer?.

Chemi J, Villoldo G Bladder (San Franc). 2023; 10:e21200002.

PMID: 37006950 PMC: 10062473. DOI: 10.14440/bladder.2023.848.

References

White I, Royston P, Wood A . Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011; 30(4):377-99. DOI: 10.1002/sim.4067. View

Cohen D, Reynolds M . Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol. 2008; 52(25):2119-26. PMC: 2716087. DOI: 10.1016/j.jacc.2008.09.018. View

van Rhijn B, Burger M . Bladder cancer: Low adherence to guidelines in non-muscle-invasive disease. Nat Rev Urol. 2016; 13(10):570-1. DOI: 10.1038/nrurol.2016.165. View

Leal J, Luengo-Fernandez R, Sullivan R, Witjes J . Economic Burden of Bladder Cancer Across the European Union. Eur Urol. 2015; 69(3):438-47. DOI: 10.1016/j.eururo.2015.10.024. View

Feifer A, Xie X, Brophy J, Segal R, Kassouf W . Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Urology. 2010; 76(3):652-6. DOI: 10.1016/j.urology.2009.12.070. View

Willan A, Briggs A, Hoch J . Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ. 2004; 13(5):461-75. DOI: 10.1002/hec.843. View

Sylvester R, Oosterlinck W, Holmang S, Sydes M, Birtle A, Gudjonsson S . Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial.... Eur Urol. 2015; 69(2):231-44. DOI: 10.1016/j.eururo.2015.05.050. View

Ploeg M, Aben K, Kiemeney L . The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27(3):289-93. PMC: 2694323. DOI: 10.1007/s00345-009-0383-3. View

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

10.

Svatek R, Hollenbeck B, Holmang S, Lee R, Kim S, Stenzl A . The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014; 66(2):253-62. DOI: 10.1016/j.eururo.2014.01.006. View

11.

Bosschieter J, Nieuwenhuijzen J, van Ginkel T, Vis A, Witte B, Newling D . Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. Eur Urol. 2017; 73(2):226-232. DOI: 10.1016/j.eururo.2017.06.038. View

12.

MacNeil Vroomen J, Eekhout I, Dijkgraaf M, van Hout H, de Rooij S, Heymans M . Multiple imputation strategies for zero-inflated cost data in economic evaluations: which method works best?. Eur J Health Econ. 2015; 17(8):939-950. PMC: 5047955. DOI: 10.1007/s10198-015-0734-5. View

13.

Attema A, Brouwer W, Claxton K . Discounting in Economic Evaluations. Pharmacoeconomics. 2018; 36(7):745-758. PMC: 5999124. DOI: 10.1007/s40273-018-0672-z. View

14.

Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson J, Long S . Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009; 115(12):2660-70. PMC: 2769205. DOI: 10.1002/cncr.24311. View

15.

Bosschieter J, Nieuwenhuijzen J, Vis A, van Ginkel T, Lissenberg-Witte B, Beckers G . An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups. Urol Oncol. 2018; 36(9):400.e7-400.e14. DOI: 10.1016/j.urolonc.2018.05.026. View

16.

Lee C, Barocas D, Globe D, Oefelein M, Colayco D, Bruno A . Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. J Urol. 2012; 188(6):2114-9. DOI: 10.1016/j.juro.2012.08.005. View

17.

Moher D, Hopewell S, Schulz K, Montori V, Gotzsche P, Devereaux P . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340:c869. PMC: 2844943. DOI: 10.1136/bmj.c869. View